Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01793766 · ClinicalTrials.gov registry record · Phase 1

Non-invasive Brain Modulation for Weight Maintenance

A Phase 1 study, sponsored by Massachusetts General Hospital.

Terminated
Registry status
Phase 1
Development phase
13
Enrollment target

NCT01793766: Clinical Trial Phase 1 study, sponsored by Massachusetts General Hospital.

NCT01793766 is a Phase 1 study that was terminated before completion, run by Massachusetts General Hospital. The registered enrollment target is 13 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (78% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist → Add completion date to calendar (.ics) →

The verdict

NCT01793766, a Phase 1 study, was terminated before completion, sponsored by Massachusetts General Hospital.

TERMINATED
Registry status
Phase 1
Development phase
13 participants
Enrollment target

Study Summary

This is a study of overweight men and women. Everybody will receive a very low calorie diet to eat in place of meals for 10 weeks. During the last two weeks of the diet, half of the patients will receive an intervention to activate parts of their brain that can help them eat less. The other half of the patient will receive a placebo or sham intervention. The intervention will involve a small electric current given every day for 10 days. Everybody will be monitored for 16 more weeks (total of 26 weeks) while on a weight maintenance diet to see if the intervention helps people keep the weight off.

Primary Outcome

Patients will be placed on a very low calorie diet from baseline to week 11. The primary end point is the maintenance of weight loss from week 11 to week 26 after the very low calorie diet is stopped.

Interventions

  • DEVICE Sham modulation
  • DEVICE Brain modulation

Trial Details

FieldValue
Enrollment Target 13 participants
Start Date 2013-05
Est. Completion 2015-06
Phase Phase 1
Massachusetts General Hospital

2,032 total trials

Why NCT01793766 stopped before completion

NCT01793766 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 13 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (78% lower).

The record links to 0 conditions, and to 2 interventions - of which Sham modulation is the first listed.

NCT01793766 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT01793766 about?

NCT01793766 is a clinical study titled "Non-invasive Brain Modulation for Weight Maintenance". This is a study of overweight men and women. Everybody will receive a very low calorie diet to eat in place of meals for 10 weeks. During the last two weeks of the diet, half of the patients will receive an intervention to activate parts of their brain that can help them eat less. The other half of ...

What is the current status of trial NCT01793766?

This trial is currently terminated. It is a Phase 1 study. The enrollment target is 13 participants. The study started on 2013-05. Estimated completion is 2015-06.

What interventions are being tested in trial NCT01793766?

The interventions under investigation include: Sham modulation (DEVICE), Brain modulation (DEVICE).

Who is sponsoring clinical trial NCT01793766?

This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT01793766's enrollment target sits among peer trials

13 1847th of 2000 higher than 149 of 2,000 other Phase 1 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03125655 · 13 participants

    Regulation of Inflammatory Genes in Psoriasis

  • NCT03774446 · 13 participants · Phase 2

    Multicenter Study of Seliciclib (R-roscovitine) for Cushing Disease

  • NCT03830151 · 13 participants · Phase 1

    Hyperpolarized Carbon C 13 Pyruvate in Diagnosing Glioma in Patients With Brain Tumors

  • NCT04573231 · 13 participants · Phase 2

    Evaluation of PSMA in HER2- AR+ Metastatic Breast Cancer

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01793766, the US trial registry maintained by the National Library of Medicine. NCT01793766 (small enrollment · none site footprint · terminated) retrieved and formatted by PlainTrial, see methodology.